NCT06946420View on ClinicalTrials.gov

SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

January 10, 2030

Study Completion Date

January 10, 2031

Conditions
Radiation TherapySBRTPancreatic Cancer Metastatic
Interventions
RADIATION

SBRT or RT on primary pancreatic and/or metastatic distant lesions before chemotherapy

This group of patients will first undergo radiotherapy on the primary pancreatic lesion and stereotactic treatment on the metastatic sites before being started on standard systemic therapy (chemotherapy)

DRUG

Standard systemic therapy (chemotherapy) without RT/SBRT

This group of patients will undergo standard systemic therapy (chemotherapy drugs chosen by oncologist) without radiotherapy treatment

Trial Locations (1)

00168

Policlinico Universitario Agostino Gemelli IRCSS, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT06946420 - SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy | Biotech Hunter | Biotech Hunter